CD81 sequence and susceptibility to hepatitis C infection
- 3 October 2013
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (1), 162-168
- https://doi.org/10.1002/jmv.23726
Abstract
Several cell surface molecules have hepatitis C virus (HCV) binding properties and may serve as receptors facilitating viral entry into cells. The large extracellular loop (LEL) of CD81 has been shown to bind the HCV envelope protein E2 with several critical residues for the CD81-HCV-E2 interaction. It was hypothesised that variation in the CD81 LEL sequence may modify susceptibility to HCV infection. HCV RNA negative patients with spontaneous viral clearance (RNA −ve); HCV RNA positive cases, who are affected chronically (RNA +ve); and patients at high risk of HCV infection, exposed but uninfected patients (EU) were studied. Genomic DNA was extracted from whole blood samples and four exons of the CD81 LEL gene were amplified by PCR and sequenced. The cDNA derived from CD81 (≈700 bp) was sequenced following RNA extraction from peripheral blood mononuclear cells. Patients, who are RNA positive, RNA negative, and exposed uninfected were sequenced for four DNA sections (A, B, C, and D). Sixty-two (43M:19F) patients, from all the patient cohorts, were sequenced and compared for the C section alone (which encompasses the important binding region of the molecule for envelope protein) including 21 (14M:7F) HCV RNA negative, 15 (10M:5F) HCV RNA positive and 26 (20M:6F) exposed uninfected and no sequence differences were observed. The entire CD81 sequence from cDNA was obtained in 23 cases—11 RNA −ve, 5 RNA +ve and 7 EU. In 7 of the 23 cases, the nucleotides were confirmed with the genomic sequence (4 RNA −ve and 3 EU cases). No sequence variation was found in any of the patients studied by either method, including gene sections encoding the residues most important for CD81-HCV E2 binding. The LEL of CD81 is a molecule that is highly conserved. No differences in nucleotide sequence influencing susceptibility to, or outcome of HCV infection or evidence of methylation of the gene were found. J. Med. Virol. 86:162–168, 2014.Keywords
This publication has 27 references indexed in Scilit:
- Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing AntibodiesGastroenterology, 2012
- Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection*Journal of Viral Hepatitis, 2005
- HCV and HIV binding lectin, DC-SIGNR, is expressed at all stages of HCV induced liver diseaseJournal of Clinical Pathology, 2004
- In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopesProceedings of the National Academy of Sciences of the United States of America, 2003
- L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virusProceedings of the National Academy of Sciences of the United States of America, 2003
- Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infectionGenes & Immunity, 2002
- Critical role of CD81 in cognate T–B cell interactions leading to Th2 responsesInternational Immunology, 2002
- Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope ProteinThe Journal of Experimental Medicine, 2001
- Discovery of non-A, non-B hepatitis and identification of its etiologyAmerican Journal Of Medicine, 1999
- Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemiaGut, 1999